Integra LifeSciences Holdings Corporation

NasdaqGS:IART Stock Report

Market Cap: US$2.0b

Integra LifeSciences Holdings Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Mojdeh Poul

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure3.8yrs
Board average tenure11.8yrs

Recent management updates

Recent updates

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Extensively

Jan 31
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Extensively

There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise

Nov 05
There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise

Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Oct 24
Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S

Sep 08
Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S

Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?

Aug 21
Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?

At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Jul 01
At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Integra LifeSciences Still Underperforming As Manufacturing Issues Linger

Jun 21

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

May 28
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

Feb 27
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Feb 11
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jan 14
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Dec 31
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Dec 03
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Nov 06
Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Oct 24
Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Sep 22
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Aug 15
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Jul 03
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jun 19
Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

May 05
Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Apr 07
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

Mar 26
Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Mar 14
At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Feb 27
Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Feb 02
Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Jan 05
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return

Dec 21
Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return

CEO

Mojdeh Poul (60 yo)

less than a year

Tenure

Ms. Mojdeh Poul is President, CEO & Director of Integra LifeSciences Holdings Corporation from January 6, 2025. Ms. Poul serves as Independent Director at iRhythm Technologies, Inc. since June 1, 2023. She...


Leadership Team

NamePositionTenureCompensationOwnership
Stuart Essig
Non- Executive Chairman27.2yrsUS$422.52k2.27%
$ 45.7m
Lea Knight
Executive VP & CFO1.7yrsUS$1.67m0.054%
$ 1.1m
Jeffrey Mosebrook
Senior VP of Finance & Principal Accounting Officer7.3yrsUS$1.25m0.047%
$ 940.1k
Eric Schwartz
Executive VP6.3yrsUS$1.62m0.077%
$ 1.6m
Robert Davis
Executive VP & President of Tissue Technologies12.2yrsUS$1.42m0.084%
$ 1.7m
Michael McBreen
Executive VP & President of Codman Specialty Surgical4.8yrsUS$2.83m0.073%
$ 1.5m
Mojdeh Poul
Presidentless than a yearno datano data
Stephen Leonard
Corporate VP of Global Operations & Supply Chain4.5yrsno datano data
Laurene Isip
Vice President of Global Corporate Communications & Public Relationsno datano datano data
Ruth Fleming
Vice President of Global Marketingno datano datano data
Chantal Veillon-Berteloot
Executive VP & Chief Human Resources Officer2.1yrsno data0.032%
$ 635.0k
Mark Jesser
Corporate VP & Chief Digital Officer3.1yrsno datano data

3.8yrs

Average Tenure

58yo

Average Age

Experienced Management: IART's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Stuart Essig
Non- Executive Chairman27.2yrsUS$422.52k2.27%
$ 45.7m
Mojdeh Poul
Presidentless than a yearno datano data
Raymond Murphy
Independent Director15.8yrsUS$297.54k0.11%
$ 2.2m
Christian Schade
Independent Director19.1yrsUS$293.28k0.082%
$ 1.7m
Barbara Hill
Independent Presiding Director11.8yrsUS$342.54k0.18%
$ 3.6m
Keith N. Bradley
Independent Director33.1yrsUS$306.31k0.091%
$ 1.8m
Jeffrey Graves
Independent Director1.2yrsUS$90.68k0.016%
$ 325.4k
Shaundra Clay
Independent Director3.8yrsUS$260.04k0.028%
$ 571.1k
Renee Lo
Independent Director2.6yrsUS$297.54k0.021%
$ 420.7k

11.8yrs

Average Tenure

63yo

Average Age

Experienced Board: IART's board of directors are seasoned and experienced ( 11.8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/05 01:04
End of Day Share Price 2025/02/05 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Integra LifeSciences Holdings Corporation is covered by 30 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Matthew TaylorBarclays
Charley JonesBarrington Research Associates, Inc.